公开(公告)号：US20160185826A1

公开(公告)日：2016-06-30

申请号：US15015249

申请日：2016-02-04

Applicant: Medigen Biotechnology Corp.

Inventor： Young-Sun LIN ,  Jinyi CHENG ,  Ya-Lin CHIANG ,  Ming-Cheng CHEN ,  Kuei-Tai A. LAI ,  Chih Ya YANG

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K39/125 ,  A61K39/15 ,  C12N7/00 ,  A61K39/145

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2720/12371 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10171 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/16022 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16071 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/28171 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  C12N2770/32422 ,  C12N2770/32423 ,  C12N2770/32434 ,  C12N2770/32471 ,  Y02A50/467

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Abstract translation: 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：US20240261386A1

公开(公告)日：2024-08-08

申请号：US18165762

申请日：2023-02-07

Applicant: KING FAISAL UNIVERSITY

Inventor： JAWHAR GHARBI ,  MOHAMMED A. ALMALKI ,  AMEERA ALYAMI ,  MANEL BEN M'HADHEB

IPC: A61K39/125 ,  A61K9/48 ,  A61P31/14 ,  C07K14/005

CPC classification number: A61K39/125 ,  A61K9/485 ,  A61P31/14 ,  C07K14/005 ,  A61K2039/5254 ,  A61K2039/54 ,  C12N2770/32321 ,  C12N2770/32322 ,  C12N2770/32334 ,  C12N2770/32371

Abstract: The Coxsackievirus B3 (CVB3) vaccine including a mutant strain of Coxsackievirus B3 (CVB3) (SEQ ID NO: 1) has specific double mutations introduced in the Internal Ribosome Entry Segment (IRES) region of the wild type Coxsackievirus B3 (CVB3) genome in the nucleotide positions 473 (in which uracil is substituted for cytosine) and 475 (in which cytosine is substituted for uracil). The resulting double mutant (SEQ ID NO: 1) demonstrates a significant decrease in its replicative capacity and a drastic decrease in its translation efficiency compared to the wild-type Coxsackievirus B3 (CVB3) strain.

公开(公告)号：US20170056491A1

公开(公告)日：2017-03-02

申请号：US15307926

申请日：2015-03-26

Applicant: National Health Research Institutes ,  Lu-hai Wang

Inventor： Yen-Hung Chow ,  Yueh-Liang Tsou ,  Pele Choi-Sing Chong

IPC: A61K39/125

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/10323 ,  C12N2710/10343 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  Y02A50/466

Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Abstract translation: 本发明涉及用于产生针对肠道病毒感染的免疫的重组腺病毒载体。 在一个实施方案中，本发明的重组腺病毒载体包含编码肠道病毒的PI蛋白和3CD蛋白酶的表达盒。 在另一个实施方案中，本发明的重组腺病毒载体包含编码肠病毒的3C蛋白酶或3CD蛋白酶的表达盒。 本发明还涉及包含如上所述的重组腺病毒载体的疫苗组合物。 提供了使用重组腺病毒载体和疫苗组合物诱导受试者免疫应答的方法。 还提供了通过在哺乳动物细胞中表达本文所述的腺病毒载体来产生病毒样肠道病毒颗粒的方法。

公开(公告)号：US20150140027A1

公开(公告)日：2015-05-21

申请号：US14402495

申请日：2012-11-01

Applicant: SENTINEXT THERAPEUTICS Sdn Bhd

Inventor： Mary Jane Cardosa ,  Mohamad Fakruddin Jamiluddin ,  Sharifah Binti Hamid

IPC: A61K39/125 ,  C12N7/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/13 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/14043 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.

公开(公告)号：US20180271971A1

公开(公告)日：2018-09-27

申请号：US15964198

申请日：2018-04-27

Applicant: SENTINEXT THERAPEUTICS Sdn Bhd

Inventor： Mary Jane CARDOSA ,  Mohamad Fakruddin Jamiluddin ,  Sharifah Binti Hamid

IPC: A61K39/125 ,  C12N7/00 ,  A61K39/12 ,  A61K39/13 ,  A61K39/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/13 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/14043 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.

公开(公告)号：US20180243400A1

公开(公告)日：2018-08-30

申请号：US15964211

申请日：2018-04-27

Applicant: SENTINEXT THERAPEUTICS Sdn Bhd

Inventor： Mary Jane CARDOSA ,  Mohamad Fakruddin JAMILUDDIN ,  Sharifah Binti HAMID

IPC: A61K39/125 ,  C12N7/00 ,  A61K39/12 ,  A61K39/13 ,  A61K39/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/13 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/14043 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.

公开(公告)号：US10004796B2

公开(公告)日：2018-06-26

申请号：US15307926

申请日：2015-03-26

Applicant: National Health Research Institutes

Inventor： Yen-Hung Chow ,  Yueh-Liang Tsou ,  Pele Choi-Sing Chong

IPC: A61K48/00 ,  C12N15/861 ,  C12N15/00 ,  A61K38/00 ,  C12N15/63 ,  A61K39/125 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/10323 ,  C12N2710/10343 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  Y02A50/466

Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

公开(公告)号：US20170348366A1

公开(公告)日：2017-12-07

申请号：US15406459

申请日：2017-01-13

Applicant: VIRALYTICS LIMITED

Inventor： Darren R. Shafren

IPC: A61K35/768 ,  A61K9/00 ,  G01N33/50 ,  C12N7/00 ,  C12Q1/02

CPC classification number: A61K35/768 ,  A61K9/0019 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  C12Q1/025 ,  G01N33/5011

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

公开(公告)号：US20170000832A1

公开(公告)日：2017-01-05

申请号：US15121517

申请日：2015-02-27

Applicant: VIRALYTICS LIMITED

Inventor： Darren Shafren ,  Gough Geoffrey Au

IPC: A61K35/768 ,  C12N7/00 ,  A61K39/395 ,  A61K9/00

CPC classification number: A61K35/768 ,  A61K9/0019 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/54 ,  A61K2039/572 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  A61K2300/00

Abstract: The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.

Abstract translation: 本发明涉及治疗肿瘤的方法，包括通过直接注射或全身给药或将肿瘤内施用于肿瘤或癌症与通过全身途径共同施用免疫刺激剂一起递送溶瘤病毒或溶瘤病毒RNA至 哺乳动物。

公开(公告)号：US20240252564A1

公开(公告)日：2024-08-01

申请号：US18196538

申请日：2021-08-04

Applicant: Technische Universität Berlin

Inventor： Henry FECHNER ,  Ahmet HAZINI

IPC: A61K35/768 ,  A61P35/00 ,  C12N15/86

CPC classification number: A61K35/768 ,  A61P35/00 ,  C12N15/86 ,  C12N2770/32322 ,  C12N2770/32332 ,  C12N2770/32343 ,  C12N2770/32345 ,  C12N2770/32371

Abstract: The present invention related to an infectious complementary DNA (cDNA) construct characterized in that the cDNA comprises: —the cDNA of the CVB3 genomic RNA sequence of a Coxsackievirus B3 (CVB3); —at least one or more microRNA target sequences (miR-TS), which are complementary to one or more microRNAs having tissue-specific expression pattern, wherein the at least one or more miR-TS are integrated immediately adjacent of the 5′UTR and/or the 3′UTR of the CVB3 protein coding sequence.